Investigator Perspectives on Emerging Concepts in the Management of Genitourinary CancersEverolimus as second-line treatment for mRCC
0:42 minutes.
TRANSCRIPTION:
DR LOVE: How do you choose between going to everolimus versus another TKI? DR PETRYLAK: Generally, one of the things I tend to look at is the duration of response on the first TKI. And that tends to correlate with a response to a second one. But unfortunately, we don’t have a marker to tell us whether they should go on another TKI or whether they’ll be more susceptible to an mTOR inhibitor at that particular point. So we do need good molecular markers to tell us what to do. DR LOVE: Have you had patients you thought had prolonged benefit from the drug? DR PETRYLAK: I’ve seen benefits of about 6 to 9 months with this drug. That’s just about the limit I’ve seen with it. DR LOVE: And how about tolerability? DR PETRYLAK: It’s fairly well tolerated. I think fatigue is the major thing I hear complaints about. |